BioInvent’s primary goal is to develop next generation immuno-oncology drugs with a focus on improving therapeutic results in areas with significant unmet need. Our strategy is to leverage on our expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
A TRANSFORMATION OF CANCER TREATMENT
Immunotherapy encompasses a broad range of treatments that work in synergy with the body’s natural immune defense in order to tackle disease. In cancer, in particular, immunotherapy has already provided a paradigm shift: in a few patients with cancers that continue to grow or spread despite multiple numerous conventional treatments, immunotherapies have stopped tumor growth in its track, or even shrunk the tumor.
The aim of the R&D programs at BioInvent is to improve on those first early steps, developing immunotherapies that not only serve as mainstream treatments for cancer, but also push toward the real cures in oncology.
BUSINESS MODEL
BioInvent has three main areas for commercialization. The Company’s primary value drivers are clinical and preclinical development projects. BioInvent also has research and development collaborations based on the Company’s technology platform F.I.R.S.T™ and its antibody library n-CoDeR®.
BioInvent’s manufacturing facility provides capacity to produce antibodies for the Company’s preclinical studies and clinical trials, which is mandatory for a swift preclinical/ clinical development path. The manufacturing facility provides also the opportunity to manufacture and sell antibodies to external parties.